Teodora Schellato, DO
Urology · Philadelphia, PANPI 1184839698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,700 of the $41,290 with a category attached, or 67.1%. Medtronic accounts for 75.7% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2020 at $7,834 and has fallen 71.4% since, to $2,240 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $86.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$31K
- Dendreon Pharmaceuticals LLC$1K
- Sumitomo Pharma America, Inc.$1K
- Astellas Pharma US Inc$831
- AbbVie$788
- Johnson & Johnson$569
- plus $6K from 51 others
What the payments were for
- Speaking & faculty fees$27,70067%
- Food & beverage$13,17732%
- Education$4131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,290 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 709 | $502,372 |
| OrgovyxRelugolix | 126 | $326,595 |
| MyrbetriqMirabegron | 417 | $237,231 |
| XtandiEnzalutamide | 11 | $158,454 |
| Abiraterone Acetate | 22 | $74,344 |
| ElmironPentosan Polysulfate Sodium | 43 | $43,451 |
| Solifenacin Succinate | 506 | $25,321 |
| Tamsulosin Hcl | 1,639 | $18,741 |
| Trospium Chloride ErTrospium Chloride | 122 | $18,282 |
| PremarinEstrogens, Conjugated | 19 | $12,070 |
| Finasteride | 599 | $10,074 |
| Mirabegron ErMirabegron | 15 | $7,119 |
| Silodosin | 69 | $6,533 |
| Tadalafil | 89 | $6,150 |
| Methenamine Hippurate | 175 | $5,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $1,060 | $828,967835 claims |
| Astellas Pharma US IncMyrbetriq, Xtandi | $831 | $395,684428 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $106 | $74,34422 claims |
| PfizerPremarin | $229 | $12,07019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.